» Articles » PMID: 24574544

Elevated High-density Lipoprotein Cholesterol and Cardiovascular Mortality in Maintenance Hemodialysis Patients

Overview
Date 2014 Feb 28
PMID 24574544
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High-density lipoprotein (HDL) confers protection against atherosclerosis by several different mechanisms. Although in the general population, increasing levels of HDL are associated with reduced cardiovascular (CV) mortality, this association is not well known in patients with chronic disease states such as end-stage renal disease. We hypothesize that the association of serum HDL concentration and its ratio to total cholesterol with all-cause and CV mortality in hemodialysis patients is different from the general population.

Methods: A 3-year (July 2004 to June 2007) cohort of 33 109 chronic hemodialysis patients was studied in the USA in the dialysis clinics where lipid profile was measured in at least 50% of all outpatients of the clinic during a given calendar quarter. Cox proportional hazard models were adjusted for demographics and case-mix variables and cubic splines were plotted.

Results: Higher HDL concentrations up to 50 mg/dL were associated with better overall survival, while HDL at 60 mg/dL and above was associated with a rise in all-cause and CV mortality. All-cause and CV mortality hazard ratio was 1.28 (1.20-1.38) and 1.08 (1.01-1.16) for HDL <30 mg/dL and 1.05 (1.00-1.10) and 1.08 (1.00-1.16) for HDL ≥ 60 mg/dL, respectively (reference: HDL: 30-<60 mg/dL).

Conclusions: In contrast to the general population, low total cholesterol to HDL ratio was associated with higher mortality in hemodialysis patients. A U-shaped association between HDL cholesterol level and all-cause and CV mortality exists in hemodialysis patients with HDL between 50 and <60 mg/dL exhibiting the best survival. The underlying mechanisms responsible for these seemingly paradoxical associations await further investigation.

Citing Articles

High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?.

Liu K, Cooper M, Chai Z, Liu F Int J Mol Sci. 2025; 26(4).

PMID: 40004147 PMC: 11855193. DOI: 10.3390/ijms26041683.


Prognostic Features for Overall Survival in Male Diabetic Patients Undergoing Hemodialysis Using Elastic Net Penalized Cox Regression; A Machine Learning Approach.

Sharifi M, Mousavi-Roknabadi R, Ebrahimi V, Sadegh R, Dehbozorgi A, Hosseini-Marvast S Arch Iran Med. 2025; 28(1):9-17.

PMID: 40001324 PMC: 11862393. DOI: 10.34172/aim.27746.


Serum HDL-C subfractions as predictors of cardiovascular calcification in hemodialysis patients: novel insights and clinical implications.

Li D, Sun W, Zhou X, Wen Y, Zou Y Front Med (Lausanne). 2024; 11:1391057.

PMID: 39144664 PMC: 11322615. DOI: 10.3389/fmed.2024.1391057.


Association of remnant cholesterol with renal function and its progression in patients with type 2 diabetes related chronic kidney disease.

Li Q, Wang T, Shao X, Fan X, Lin Y, Cui Z Front Endocrinol (Lausanne). 2024; 15:1331603.

PMID: 39027471 PMC: 11254661. DOI: 10.3389/fendo.2024.1331603.


The Predictive Value of Atherogenic Index of Plasma, Non- High Density Lipoprotein Cholesterol (Non-HDL-C), Non-HDL-C/HDL-C, and Lipoprotein Combine Index for Stroke Incidence and Prognosis in Maintenance Hemodialysis Patients.

Ma L, Sun F, Zhu K, Han Q, Sun Q Clin Interv Aging. 2024; 19:1235-1245.

PMID: 38978964 PMC: 11230120. DOI: 10.2147/CIA.S461150.


References
1.
Calabresi L, Gomaraschi M, Franceschini G . Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003; 23(10):1724-31. DOI: 10.1161/01.ATV.0000094961.74697.54. View

2.
Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

3.
Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K . Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis. 2011; 220(2):493-501. DOI: 10.1016/j.atherosclerosis.2011.10.038. View

4.
Wilensky R, Hamamdzic D . The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol. 2007; 22(6):545-51. DOI: 10.1097/HCO.0b013e3282f028fe. View

5.
Shashkin P, Dragulev B, Ley K . Macrophage differentiation to foam cells. Curr Pharm Des. 2005; 11(23):3061-72. DOI: 10.2174/1381612054865064. View